Position in INSM
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$607,734
+$255,494 QoQ
Shares Held
5,700
+62.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.40%
of 13F equity value
Holder Rank
#382
of 652 holders
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INSM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bayesian Capital Management, LP holds $2,677,814 across 10 Biotechnology names. INSM ranks #1 (22.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
This page
|
5,700 | $607,734 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
4,300 | $570,739 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
808 | $503,820 | |
| 4 | GMAB |
Genmab A/S
|
10,369 | $284,836 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
3,300 | $268,983 | |
| 6 | SMMT |
Summit Therapeutics Inc.
|
17,200 | $250,604 | |
| 7 | MDXG |
Mimedx Group, Inc.
|
18,400 | $70,840 | |
| 8 | IOVA |
Iovance Biotherapeutics, Inc.
|
15,300 | $63,648 |
All Filings in INSM
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $607,734 | 5,700 | Shares | Sole | 2026-08-14 | |
| 2025-06-30 | $352,240 | 3,500 | Shares | Sole | 2025-08-14 | |
| 2023-12-31 | $916,219 | 29,565 | Shares | Sole | 2024-02-14 | |
| 2022-12-31 | $333,586 | 16,696 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $394,095 | 18,296 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $423,000 | 18,000 | Shares | Sole | 2022-05-16 | |
| 2020-03-31 | $184,345 | 11,500 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||